Click on a filter below to refine your search. Remove a filter to broaden your search.
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.